Skip to main content

Table 1 Characteristics of 928 Swiss childhood cancer survivors invited to home collection of germline DNA, stratified by participation status

From: Predictors for participation in DNA self-sampling of childhood cancer survivors in Switzerland

  Participation Univariable logistic regression Multivariable logistic regression
Characteristic Total (n; %)a Yes (n; %)a No (n; %)a OR (95%-CI) p-value OR (95%-CI) p-value
Sex
Female 426 (46) 209 (45) 217 (47) Ref.   Ref.  
Male 502 (54) 254 (55) 248 (53) 1.06 (0.82 - 1.38) 0.64 1.09 (0.83-1.42) 0.53
Nationality
Swiss 710 (76) 377 (81) 333 (72) Ref.   Ref.  
Foreign 218 (24) 86 (19) 132 (28) 0.58 (0.42-0.78) < 0.001 0.53 (0.38-0.73) < 0.001
Correspondence language
German 633 (68) 308 (67) 325 (70) Ref.   Ref.  
French and Italian 295 (32) 155 (33) 140 (30) 1.17 (0.89-1.54) 0.27 1.31 (0.98-1.75) 0.07
Age at first neoplasm diagnosis
Median (IQR; years) 8.7 (3.0-13.4) 8.7 (3.0-13.4) 8.6 (3.6-13.3)     
0-4 years 311 (33) 166 (36) 145 (31) 1.14 (0.83 – 1.57) 0.35 1.08 (0.75-1.56) 0.4
5-9 years 212 (23) 97 (21) 115 (25) 0.84 (0.59 - 1.20)   0.79 (0.54-1.14)  
10-14 years 287 (31) 144 (31) 143 (31) Ref.   Ref.  
15-20 years 118 (13) 56 (12) 62 (13) 0.90 (0.58 - 1.38)   0.95 (0.61-1.48)  
Year of diagnosis
1976-1985 110 (12) 54 (12) 56 (12) 0.84 (0.55 - 1.30) 0.02  
1986-1995 193 (21) 78 (17) 115 (25) 0.59 (0.41 - 0.85)   
1996-2005 312 (33) 164 (35) 148 (32) 0.97 (0.71 - 1.33)   
2006-2016 313 (34) 167 (36) 146 (31) Ref.   
Diagnostic group of first primary neoplasm (ICCC-3)
Leukaemias, myeloproliferative and myelodysplastic diseases 35 (4) 14 (3) 21 (5) 0.77 (0.37-1.58) 0.38   
Lymphomas 190 (20) 95 (21) 95 (20) 1.15 (0.79-1.68)    
CNS tumours and miscellaneous intracranial and intraspinal neoplasms 256 (28) 119 (26) 137 (29) Ref.    
Neuroblastoma and other peripheral nervous cell tumours 78 (8) 45 (10) 33 (7) 1.57 (0.94-2.62)    
Retinoblastoma 44 (5) 18 (4) 26 (6) 0.8 (0.42-1.53)    
Renal tumours 33 (4) 20 (4) 13 (3) 1.77 (0.85-3.71)    
Hepatic tumours 24 (2) 15 (3) 9 (2) 1.92 (0.81-4.54)    
Malignant bone tumours 100 (11) 56 (12) 44 (9) 1.47 (0.92-2.33)    
Soft tissue and other extraosseous sarcomas 94 (10) 48 (10) 46 (10) 1.2 (0.75-1.93)    
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 64 (7) 29 (6) 35 (8) 0.95 (0.55-1.65)    
Other malignant epithelial neoplasms and malignant melanomas 6 (< 1) 2 (< 1) 4 (< 1) 0.58 (0.1-3.2)    
Langerhans cell histiocytosis 4 (< 1) 2 (< 1) 2 (< 1) 1.15 (0.16-8.3)    
Chemotherapy
No 61 (7) 25 (5) 36 (8) Ref.    
Yes 867 (93) 438 (95) 429 (92) 1.47 (0.87-2.49) 0.15   
- With platinum agents 491 (53) 259 (56) 232 (50) 1.27 (0.98-1.64) 0.07   
Radiotherapy
No 319 (34) 160 (35) 159 (34) Ref.    
Yes 609 (66) 303 (65) 306 (66) 0.98 (0.75-1.29) 0.91   
- With head radiotherapy (≥30 Gy) 343 (37) 166 (36) 177 (38) 0.91 (0.70-1.19) 0.49   
- With chest radiotherapy 328 (35) 156 (34) 172 (37) 0.87 (0.66-1.33) 0.29   
Haematopoietic stem cell transplantation
No 864 (93) 428 (92) 436 (94) Ref.    
Yes 64 (7) 35 (8) 29 (6) 1.23 (0.74-2.05) 0.43   
Relapse of first neoplasm
No 738 (80) 368 (79) 370 (80) Ref.    
Yes 190 (20) 95 (21) 95 (20) 1.01 (0.73-1.38) 0.97   
Cancer predisposition syndrome
No 879 (95) 442 (95) 437 (94) Ref.   Ref.  
Yes 49 (5) 21 (5) 28 (6) 0.74 (0.42-1.33) 0.31 0.54 (0.29-1.0) 0.05
Second primary neoplasm
No 889 (96) 438 (95) 451 (97) Ref.   Ref.  
Yes 39 (4) 25 (5) 14 (3) 1.84 (0.94-3.58) 0.07 1.92 (0.97-3.82) 0.06
Age at study invitation
Median (IQR; years) 26.5 (18.8-36.5) 25.1 (18.3-35.2) 27.7 (19.5-37.3)     
< 10 years 50 (6) 23 (5) 27 (6) 0.72 (0.4-1.32) 0.005 0.75 (0.39-1.43) 0.002
10-19 years 215 (23) 121 (26) 94 (20) 1.09 (0.77-1.56)   1.17 (0.81-1.70)  
20-29 years 296 (32) 160 (35) 136 (29) Ref.   Ref.  
30-39 years 198 (21) 78 (17) 120 (26) 0.55 (0.38-0.8)   0.54 (0.38-0.79)  
40 or more years 169 (18) 81 (17) 88 (19) 0.78 (0.54-1.14)   0.72 (0.48-1.07)  
  1. Legend: ‡, omitted from multivariable regression model for collinearity with age at study invitation; a, column percentages are indicated; CNS central nervous system, ICCC-3 international classification of childhood cancer, edition 3; IQR interquartile range; n, number